Table 2.
Correlation between the expression of IGF-IR or Cbl-b and the clinicopathological factors in primary gastric cancer patients
|
Factors |
All cases |
IGF-IR |
Cbl-b |
||||
|---|---|---|---|---|---|---|---|
| Negative (%) | Positive (%) | P value | Negative (%) | Positive (%) | P value | ||
|
Age
a
|
|
|
|
|
|
|
|
| < 59 |
46 |
15 (32.6) |
31 (67.4) |
0.749 |
22 (47.8) |
24 (52.2) |
0.278 |
| ≥ 60 |
54 |
16 (29.6) |
38 (70.4) |
20 (37.0) |
34 (63.0) |
||
|
Gender |
|
|
|
|
|
|
|
| Male |
72 |
22 (30.6) |
50 (69.4) |
0.878 |
31 (43.1) |
41 (56.9) |
0.733 |
| Female |
28 |
9 (32.1) |
19 (67.9) |
11 (39.2) |
17 (60.8) |
||
|
pTNM stage |
|
|
|
|
|
|
|
| I + II |
46 |
24 (52.2) |
22 (47.8) |
<0.001* |
6 (13.0) |
40 (87.0) |
<0.001* |
| III + IV |
54 |
7 (13.0) |
47 (87.0) |
36 (66.7) |
18 (33.3) |
||
|
Lymph node metastasis |
|
|
|
|
|
|
|
| Absent |
50 |
26 (52.0) |
24 (48.0) |
<0.001* |
6 (12.0) |
44 (88.0) |
<0.001* |
| Present |
50 |
5 (10.0) |
45 (40.0) |
36 (72.0) |
14 (28.0) |
||
|
Lauren grade |
|
|
|
|
|
|
|
| Intestinal |
22 |
8 (36.4) |
14 (63.6) |
0.614 | 7 (31.8) |
15 (68.2) |
0.452 |
| Diffuse |
46 |
12 (26.1) |
34 (73.9) |
22 (47.8) |
24 (52.2) |
||
| mixed | 32 | 11 (34.4) | 21 (65.6) | 13 (40.6) | 19 (59.4) | ||
aMean age.
*P <0.05.